Regeneron Pharmaceuticals clinical trial failures

Review 47 stopped clinical trials from Regeneron Pharmaceuticals, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 4 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials47

Likely biological signals4

Shown below47

Dominant stop reasons

OPERATIONAL: 29
OTHER/UNKNOWN: 14
EFFICACY/FUTILITY: 3
SAFETY: 1

Notable sponsors

Regeneron Pharmaceuticals: 47

Related phases

Phase II: 20
Phase I: 16
Phase III: 9
Phase IV: 2

Crawlable stopped-trial records

Open Explore

Showing up to 47 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04409080: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

Phase I Severe Aplastic Anemia (SAA) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT07428369: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase II Multiple Myeloma (MM) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT04695977: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase II Melanoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business Decision

NCT04916002: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase II Merkel Cell Carcinoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision related to study drug supply

NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Phase I Metastatic Castration-resistant Prostate Cancer trial by Regeneron Pharmaceuticals. Stop reason: SAFETY.

Due to a Dose Limiting Toxicity.

NCT06237309: REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Phase II Heart Failure trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision

NCT07187089: Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

Phase IV Severe Atopic Dermatitis (AD) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Phase I Advanced NSCLC trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision

NCT05081388: COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

Phase I SARS-CoV-2 trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT06833190: REGN5381 in Adult Participants With Uncontrolled Hypertension

Phase II Uncontrolled Hypertension trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision

NCT05169489: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Phase I Diffuse Large B Cell Lymphoma (DLBCL) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT05074433: A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Phase III Immunocompromised trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

Emerging SARS-CoV2 variants impacting susceptibility to study drug

NCT04992273: COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

Phase II COVID-19 trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

Emerging SARS-CoV-2 variants impacting susceptibility to study drug

NCT05088460: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Phase II Familial Partial Lipodystrophy trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT05092581: COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

Phase I COVID-19 trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

Emerging SARS-CoV-2 variants impacting susceptibility to study drug

NCT06970405: Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Phase I Obesity trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT04698187: CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Phase II Melanoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business Decision

NCT04633278: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase II Squamous Cell Carcinoma of Head and Neck trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business Decision

NCT03690869: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Phase I Relapsed Solid Tumor trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT05131204: Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase III Paroxysmal Nocturnal Hemoglobinuria trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision not related to efficacy or safety.

NCT04465487: Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Phase I Squamous Cell Carcinoma of Head and Neck trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT06384820: Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Phase II Cutaneous Squamous Cell Carcinoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business Decision

NCT04981717: A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Phase III Allergic Rhinitis Due to Cat Allergy trial by Regeneron Pharmaceuticals. Stop reason: EFFICACY/FUTILITY.

Lack of efficacy

NCT04863014: Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Phase II Hypertriglyceridemia trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor Decision

NCT04425629: Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Phase III COVID-19 trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

Emerging SARS-CoV-2 variants impacting susceptibility to study drug

NCT03949673: Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Phase II Osteoarthritis, Knee trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Lack of enrollment

NCT04162470: REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Phase III Paroxysmal Nocturnal Hemoglobinuria trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business Decision

NCT03515629: REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Phase III Non-small Cell Lung Cancer trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business decision

NCT03430063: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Phase II Advanced Non-Small Cell Lung Carcinoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business decision

NCT03738423: Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase II Atopic Dermatitis trial by Regeneron Pharmaceuticals. Stop reason: EFFICACY/FUTILITY.

Lack of efficacy

NCT03746704: Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

Phase I Advanced PD-L1 Positive Malignancies trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business decision

NCT04616105: Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers

Phase I Healthy Volunteer trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision

NCT04616079: Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers

Phase I Healthy Volunteer trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Sponsor decision

NCT04577820: Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Phase III Fibrodyplasia Ossificans Progressiva (FOP) trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned

NCT03736967: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase II Atopic Dermatitis trial by Regeneron Pharmaceuticals. Stop reason: EFFICACY/FUTILITY.

Lack of efficacy

NCT03956550: A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Phase II Osteoarthritis of the Knee trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee

NCT03285646: Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Phase III Chronic Low Back Pain trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Due to implementation of an urgent safety measure, enrollment and dosing in R475-PN-1612 was stopped; enrolled participants entered the 20-week safety follow-up

NCT03694197: Long Term Safety Study of PRALUENT

Phase IV Heterozygous Familial Hypercholesterolemia trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.

NCT04373083: Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Phase II Hodgkin Lymphoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Business Decision

NCT00794417: A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Phase I Advanced Carcinoma trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02418754: Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Phase II Neovascular Age-Related Macular Degeneration trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

No additional efficacy seen with REGN2176-3 over aflibercept alone

NCT03580694: Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase I Carcinoma, Non-Small-Cell Lung trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.

Program reprioritization

NCT03710941: Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Phase II Sporadic Inclusion Body Myositis trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

The study was withdrawn due to an internal decision

NCT01459796: Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

Phase III Gout trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02520245: Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Phase I Advanced Malignancies trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02284425: Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Phase I Diabetes Mellitus, Type 2 trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT01239017: A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Phase II Osteoarthritis trial by Regeneron Pharmaceuticals. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.